Serum inflammatory and immune marker response after bare-metal or drug-eluting stent implantation following percutaneous coronary intervention

Angiology

Volumn 62, Issue 2, 2011, Pages 184-190

  Moohebati, Mohsen ^a,b   Falsoleiman, Homa ^a,b   Dehghani, Mashalla ^a,b   Fazlinezhad, Afsoon ^a,b   Daloee, Mehdi Hassanzadeh ^a,b   Esmaeili, Habib ^b   Parizadeh, Seyyed Mohammad Reza ^a   Tavallaie, Shima ^a   Rahsepar, Amir Ali ^a,b   Paydar, Roghayeh ^a   Kazemi Bajestani, Seyyed Mohammad Reza ^a,b   Pourghadam Yari, Hossein ^a   Rad, Mina Akbari ^a   Zoghdar Moghadam, Talat ^b   Ghayour Mobarhan, Majid ^a,b,c   Ferns, Gordon A ^d  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITÉ DE LORRAINE   (France)

^d KEELE UNIVERSITY   (United Kingdom)

Author keywords

bare metal stent; drug eluting stent; heat shock protein 27; high sensitivity C reactive protein; percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CLOPIDOGREL; CORTICOSTEROID; HEAT SHOCK PROTEIN 27; HEPARIN;

ADULT; ANTIBODY TITER; ARTERY RUPTURE; ARTICLE; BARE METAL STENT; BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; DISEASE MARKER; DRUG ELUTING STENT; FEMALE; HEAT SHOCK; HUMAN; IMMUNE RESPONSE; IMPLANTATION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RESTENOSIS; SERUM; SHOCK; STABLE ANGINA PECTORIS;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ANTIBODIES; C-REACTIVE PROTEIN; COHORT STUDIES; CORONARY STENOSIS; DRUG-ELUTING STENTS; EQUIPMENT DESIGN; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPIDS; MALE; METALS; MIDDLE AGED; PROTEIN-SERINE-THREONINE KINASES;

EID: 78651403747     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319710375086     Document Type: Article

References (31)

1. Ghayour-Mobarhan M., Rahsepar AA, Tavallaie S., Rahsepar S., Ferns GA The potential role of heat shock proteins in cardiovascular disease: evidence from in vitro and in vivo studies. Adv Clin Chem. 2009 ; 48: 27-72.
2. Oberhoff M., Herdeg C., Baumbach A., Karsch KR Stent-based antirestenotic coatings (sirolimus/paclitaxel). Catheter Cardiovasc Interv. 2002 ; 55 (3). 404-408.
3. Kiemeneij F, Serruys PW, Macaya C., et al. Continued benefit of coronary stenting versus balloon angioplasty: five-year clinical follow-up of Benestent-I trial. J Am Coll Cardiol. 2001 ; 37 (6). 1598-1603.
4. Kornowski R., Hong MK, Tio FO, Bramwell O., Wu H., Leon MB In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 1998 ; 31 (1). 224-230.
5. Lindquist S. The heat-shock response. Annu Rev Biochem. 1986 ; 55: 1151-1191.
6. Martin JL, Mestril R., Hilal-Dandan R., Brunton LL, Dillmann WH Small heat shock proteins and protection against ischemic injury in cardiac myocytes. Circulation. 1997 ; 96 (12). 4343-4348.
7. Martin JL, Hickey E., Weber LA, Dillmann WH, Mestril R. Influence of phosphorylation and oligomerization on the protective role of the small heat shock protein 27 in rat adult cardiomyocytes. Gene Expr. 1999 ; 7 (4-6). 349-355.
8. Shams S., Shafi S., Bodman-Smith K., Williams P., Mehta S., Ferns GA Anti-heat shock protein-27 (Hsp-27) antibody levels in patients with chest pain: association with established cardiovascular risk factors. Clin Chim Acta. 2008 ; 395 (1-2). 42-46.
9. Ghayour-Mobarhan M., Sahebkar A., Parizadeh SM, et al. Antibody titres to heat shock protein 27 are elevated in patients with acute coronary syndrome. Int J Exp Pathol. 2008 ; 89 (3). 209-215.
10. Atar I., Gulmez O., Atar A., et al. The effects of prior beta-blocker therapy on serum C-reactive protein levels after percutaneous coronary intervention. Clin Cardiol. 2005 ; 28 (5). 243-246.
11. Hurlimann J., Thorbecke GJ, Hochwald GM The liver as the site of C-reactive protein formation. J Exp Med. 1966 ; 123 (2). 365-378.
12. Burke AP, Tracy RP, Kolodgie F., et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation. 2002 ; 105 (17). 2019-2023.
13. Kazemi-Bajestani SM, Ghayour-Mobarhan M., Ebrahimi M., Moohebati M., Esmaeili HA, Ferns GA C-reactive protein associated with coronary artery disease in Iranian patients with angiographically defined coronary artery disease. Clin Lab. 2007 ; 53 (1-2). 49-56.
14. Ferreiros ER, Boissonnet CP, Pizarro R., et al. Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation. 1999 ; 100 (19). 1958-1963.
15. Gaspardone A., Crea F., Versaci F., et al. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. Am J Cardiol. 1998 ; 82 (4). 515-518.
16. Gottsauner-Wolf M., Zasmeta G., Hornykewycz S., et al. Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J. 2000 ; 21 (14). 1152-1158.
17. Crea F., Gaspardone A., Tomai F., et al. Risk factors in schoolchildren associated with a family history of unheralded myocardial infarction or uncomplicated stable angina in male relatives. J Am Coll Cardiol. 1994 ; 23 (6). 1472-1478.
18. Kefer JM, Galanti LM, Desmet S., Deneys V., Hanet CE Time course of release of inflammatory markers after coronary stenting: comparison between bare metal stent and sirolimus-eluting stent. Coron Artery Dis. 2005 ; 16 (8). 505-509.
19. Li JJ, Qin XW, Yang XC, et al. Randomized comparison of early inflammatory response after sirolimus-eluting stent vs bare metal stent implantation in native coronary lesions. Clin Chim Acta. 2008 ; 396 (1-2). 38-42.
20. Rebeiz AG, Zoghbi E., Harb R., et al. Comparison of the systemic levels of inflammatory markers after percutaneous coronary intervention with bare metal versus sirolimus-eluting stents. J Interv Cardiol. 2009 ; 22 (2). 169-174.
21. Klitkou J., Jensen LO, Hansen HS, Thayssen P. High sensitive Creactive protein and interleukin 6 are not related to neointimal hyperplasia in paclitaxel eluting stents or bare metal stents. An intravascular ultrasound study. Int J Cardiol. 2007 ; 119 (1). 114-116.
22. Kochiadakis GE, Marketou ME, Arfanakis DA, et al. Reduced systemic inflammatory response to implantation of sirolimus-eluting stents in patients with stable coronary artery disease. Atherosclerosis. 2007 ; 194 (2). 433-438.
23. de la Torre-Hernandez JM, Sainz-Laso F., Burgos V., et al. Comparison of C-reactive protein levels after coronary stenting with bare metal versus sirolimus-eluting stents. Am J Cardiol. 2005 ; 95 (6). 748-751.
24. Gaspardone A., Versaci F., Tomai F., et al. C-Reactive protein, clinical outcome, and restenosis rates after implantation of different drug-eluting stents. Am J Cardiol. 2006 ; 97 (9). 1311-1316.
25. Gogo PB Jr, Schneider DJ, Watkins MW, Terrien EF, Sobel BE, Dauerman HL Systemic inflammation after drug-eluting stent placement. J Thromb Thrombolysis. 2005 ; 19 (2). 87-92.
26. Kim JY, Ko YG, Shim CY, et al. Comparison of effects of drug-eluting stents versus bare metal stents on plasma C-reactive protein levels. Am J Cardiol. 2005 ; 96 (10). 1384-1388.
27. Ozer N., Tangurek B., Firat F., et al. Effects of drug-eluting stents on systemic inflammatory response in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Heart Vessels. 2008 ; 23 (2). 75-82.
28. Mukherjee M., De BC, Jewitt D., Kakkar VV Association of antibodies to heat-shock protein-65 with percutaneous transluminal coronary angioplasty and subsequent restenosis. Thromb Haemost. 1996 ; 75 (2). 258-260.
29. Wilson GJ, Nakazawa G., Schwartz RS, et al. Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. Circulation. 2009 ; 120 (2). 141-142.
30. Wick G., Schett G., Amberger A., Kleindienst R., Xu Q. Is atherosclerosis an immunologically mediated disease ? Immunol Today. 1995 ; 16 (1). 27-33.
31. Neyt M., Van BH, Devriese S., De LC Cost-effectiveness analyses of drug eluting stents versus bare metal stents: a systematic review of the literature. Health Policy. 2009 ; 91 (2). 107-120.